Capital Research Global Investors
AZN icon

Capital Research Global Investors’s AstraZeneca AZN Stock Holding History

Capital Research Global Investors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$787M Sell
4,197,587
-413,589
-9% -$77.8M 0.11% 135
2026
Q1 		$902M Buy
4,611,176
+4,403,395
+2,119% +$849M 0.14% 123
2025
Q4 		$38.2M Sell
207,781
-184,849
-47% -$32.4M 0.01% 366
2025
Q3 		$60.2M Buy
392,630
+4,153
+1% +$629K 0.01% 338
2025
Q2 		$54.3M Buy
388,477
+3,093
+0.8% +$433K 0.01% 340
2025
Q1 		$56.7M Buy
385,384
+1,520
+0.4% +$220K 0.01% 347
2024
Q4 		$50.3M Sell
383,864
-156,245
-29% -$21.9M 0.01% 357
2024
Q3 		$84.2M Sell
540,109
-157,403
-23% -$25.4M 0.02% 298
2024
Q2 		$109M Buy
697,512
+2,183
+0.3% +$328K 0.02% 266
2024
Q1 		$94.2M Sell
695,329
-173,004
-20% -$22.9M 0.02% 292
2023
Q4 		$117M Buy
868,333
+110,257
+15% +$14.3M 0.03% 266
2023
Q3 		$103M Buy
758,076
+189,361
+33% +$25.9M 0.03% 272
2023
Q2 		$81.4M Buy
568,715
+50,988
+10% +$7.5M 0.02% 295
2023
Q1 		$71.9M Buy
+517,727
New +$69.7M 0.02% 302
2013
Q4 		– Sell
-1,171,000
Closed -$60.8M – 432
2013
Q3 		$60.8M Buy
+1,171,000
New +$58.8M 0.02% 318

Other funds holding AZN

EPGL
Evelyn Partners Group Ltd London $46.9B AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $148B AUM
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Capital Research Global Investors's AZN Position: Q2 2026 in Review

Capital Research Global Investors reduced its AstraZeneca (AZN) stake by 9% in Q2 2026, selling an estimated $77.8M and leaving 4,197,587 shares worth $787M. The position accounts for 0.11% of the portfolio, ranked #135.

Capital Research Global Investors first reported a position in AZN in Q3 2013 and has held it in 15 quarters since. The position peaked at $902M in Q1 2026. 1,253 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Capital Research Global Investors held 4,197,587 shares of AstraZeneca worth $787M as of Q2 2026.
  • Capital Research Global Investors sold 413,589 AstraZeneca shares in Q2 2026, an estimated $77.8M.
  • AstraZeneca made up 0.11% of Capital Research Global Investors's portfolio in Q2 2026, its #135 holding.
  • Capital Research Global Investors first reported a position in AstraZeneca in Q3 2013 and has held it in 15 quarters since.
  • Capital Research Global Investors's AstraZeneca position peaked at $902M in Q1 2026.
  • 1,253 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.